Shareholder of Acumen Pharmaceuticals (ABOS) plans sale of 5,633 common shares

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. (ABOS) shareholder Derek Meisner filed a notice of proposed sale on Form 144 covering 5,633 shares of common stock. The shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.

The planned sale is to be executed through Merrill Lynch on or about 01/23/2026 on the NASDAQ, with an indicated aggregate market value of $10,492.83. The filing notes that 60,573,425 shares of Acumen Pharmaceuticals common stock were outstanding at the time referenced.

The document also lists prior sales by Meisner over the past three months, including multiple common stock transactions in January 2026 with stated gross proceeds for each sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	5633	10492.83	60573425	01/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/17/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			5633	01/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7838.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	10898	21437.56
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	11770	23414.63
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	36911	67244.23
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/09/2026	5200	9169.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/12/2026	8548	14658.02
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/21/2026	2247	4063.33
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/22/2026	1054	1939.36

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Acumen Pharmaceuticals (ABOS) disclose?

The filing discloses that Derek Meisner has filed a notice of proposed sale of 5,633 shares of Acumen Pharmaceuticals, Inc. common stock, to be sold through Merrill Lynch on or about 01/23/2026 on the NASDAQ.

How many Acumen Pharmaceuticals (ABOS) shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 5,633 shares of common stock of Acumen Pharmaceuticals, Inc., with an indicated aggregate market value of $10,492.83.

How were the 5,633 Acumen Pharmaceuticals (ABOS) shares acquired by the seller?

The 5,633 shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.

What does the Form 144 say about Acumen Pharmaceuticals (ABOS) shares outstanding?

The filing states that 60,573,425 shares of Acumen Pharmaceuticals common stock were outstanding at the time referenced in the securities information section.

Which broker and exchange are involved in the planned Acumen Pharmaceuticals (ABOS) share sale?

The proposed sale will be executed through Merrill Lynch, with trades to occur on the NASDAQ stock market.

What prior Acumen Pharmaceuticals (ABOS) share sales by this seller are disclosed?

The filing lists several common stock sales by Derek Meisner during January 2026, each with its own date, share amount, and gross proceeds, such as a sale of 4,000 shares on 01/05/2026 for $7,838.00.